Michael Ulz analyst MORGAN STANLEY

Currently out of the existing stock ratings of Michael Ulz, 165 are a BUY (65.48%), 82 are a HOLD (32.54%), 5 are a SELL (1.98%).

Michael Ulz

Work Performance Price Targets & Ratings Chart

Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 49.14% that have a potential upside of 41.39% achieved within 202 days. Previously, Michael Ulz worked at BAIRD.

Michael Ulz’s has documented 485 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Financial Services, Industrials sectors.

Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 31-Jul-2026.

Wall Street Analyst Michael Ulz

Analyst best performing recommendations are on NRIX (NURIX THERAPEUTICS ).
The best stock recommendation documented was for IONS (IONIS PHARMACEUTICALS) at 11/2/2023. The price target of $45 was fulfilled within 1 day with a profit of $1.27 (2.9%) receiving and performance score of 29.04.

Average potential price target upside

ALXN Alexion Pharmaceuticals AVRO AVROBIO BMRN Biomarin Pharmaceutical FOLD Amicus Therapeutics IOVA Iovance Biotherapeutics KPTI Karyopharm Therapeutics MRTX Mirati Ther NLNK NewLink Genetics CHRS Coherus BioSciences FATE Fate Therapeutics NRIX Nurix Therapeutics  RARE Ultragenyx ALLK Allakos IGMS IGM Biosciences LUMO Lumos Pharma ISEE IVERIC bio MRSN Mersana Therapeutics BPMC Blueprint Medicines Corp YMAB Y mAbs Therapeutics AKRO Akero Therapeutics ALNY Alnylam Pharmaceuticals ALVR Allovir  CABA Cabaletta Bio IONS Ionis Pharmaceuticals ORIC Oric Pharmaceuticals  XLO Xilio Development JNCE Jounce Therapeutics FRLN Freeline Therapeutics Holdings Plc TSHA Taysha Gene Therapies  VIR Vir Biotechnology ZNTL Zentalis Pharmaceuticals Llc ALPN Alpine Immune Sciences SLN Silence Therapeutics PLC ARWR Arrowhead Pharmaceuticals DYN Dyne Therapeutics  MIRM Mirum Pharmaceuticals VKTX Viking Therapeutics GUTS Fractyl Health, Common Stock THRD Third Harmonic Bio APLS Apellis Pharmaceuticals ARGX argenx NV ADR AVEO AVEO Pharmaceuticals CNST Constellation Pharmaceuticals GNCA Genocea Biosciences HARP Harpoon Therapeutics IDRA Idera Pharmaceuticals PRTK Paratek Pharmaceuticals PRTO Proteon Therapeutics TARA Protara Therapeutics AKR Acadia Realty Trust ALL The Allstate KYTX Kyverna Therapeutics, Common Stock MACK Merrimack Pharmaceuticals THR AL Air Lease

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 03-May-2021

$173

$-9.5 (-5.21%)

$156

Hold Since 04-Feb-2021

$190

$7.5 (4.11%)

$190

Buy Since 06-Sep-2019

$175

$-7.5 (-4.11%)

$165

Buy Since 17-Jul-2017

$166

$-16.5 (-9.04%)

$175

Show more analysts

Please expand the browser size to see the chart

Which stock is Michael Ulz is most bullish on?

Potential upside of $57.39 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Michael Ulz is most reserved on?

Potential downside of $0.98 has been obtained for KPTI (KARYOPHARM THERAPEUTICS)

What Year was the first public recommendation made by Michael Ulz?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?